




RS Global Sp. z O.O. 
ISNI: 0000 0004 8495 2390 
 
Dolna 17, Warsaw, Poland 00-773 




JOURNAL World Science 
p-ISSN 2413-1032 
e-ISSN 2414-6404 
PUBLISHER RS Global Sp. z O.O., Poland 
  
ARTICLE TITLE 
MANAGEMENT OF STATUS EPILEPTICUS IN 
COMATOSE PATIENTS 
AUTHOR(S) E. Tstlidze, I. Rukhadze, I. Verulashvili 
ARTICLE INFO 
E. Tstlidze, I. Rukhadze, I. Verulashvili. (2021) Management of 
Status Epilepticus in Comatose Patients. World Science. 9(70). 
doi: 10.31435/rsglobal_ws/30092021/7691 
DOI https://doi.org/10.31435/rsglobal_ws/30092021/7691 
RECEIVED 11 August 2021 
ACCEPTED 15 September 2021 
PUBLISHED 20 September 2021 
LICENSE 
 
This work is licensed under a Creative Commons Attribution 
4.0 International License. 
 
© The author(s) 2021. This publication is an open access article. 
 
  
World Science 9(70), 2021 
 
RS Global 1 
 
MANAGEMENT OF STATUS EPILEPTICUS IN COMATOSE 
PATIENTS 
 
E. Tstlidze, Neurologiest, New Vision University Hospital, Georgia 
I. Rukhadze, Neurologiest, N. Kipshidze Central University Hospital, Georgia 





Received: 11 August 2021 
Accepted: 15 September 2021 
Published: 20 September 2021 
 
ABSTRACT 
Among the patients with different types of Epilepsy, there is one of the most 
dangerous form named - Status Epilepticus, which needs emergency 
management. Without early response and correct treatment, patient’s health 
condition may become critical up to death. The most difficult treatment of 
Status Epilepticus is in patients with unknown coma.  Under our observation, 
there were 22 patients with different etiological factors of coma. For clinical 
observation we used EEG monitoring and MRI scan in dynamics. According 
the health history of patients, we find out that 9 of them had immunological 
and unknown disorders causing Status Epilepticus. In three cases, main 
disease progression was determined without any leader etiological factors, 
which might cause immunological disorders. In 7 cases, there were non-
convulsive Status epilepticus. While all of these patients were under the 
general anesthesia, we were using anticonvulsive drugs in combination with 
immunotherapy and hormonotherapy. In two cases, we could not control 
Status Epilepticus. The EEG and MRI scan monitoring in dynamics shows 
us that difficulty in control of SE might be caused by exacerbation of the 
main disease. In conclusion, the acute disorders of central neuron system 
and early response of critical conditions are very important in correct and 
high quality management of both: Convulsive and non-Convulsive types of 
Status Epilepticus. 
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Introduction. Nowadays there are many debates about development and management status 
epilepticus (SE) in patients with coma. It is especially difficult to treat SE in patients with unknown 
coma. It is impossible to ascertain final diagnosis in some cases, though we have used different 
studies. In general, the mortality of SE is about 20 %, but it might be more than 40 % in the elderly 
with acute symptomatic SE [1-5] and many co-morbidities [6]. 
Treatment of SE, especially of refractory or super-refractory stages, is almost an “evidence-
free zone” [7]. Therefore, each clinical case is important and each clinical data must be discussed. 
Methods. There were 22 patients with coma under our observation. All patients were divide in two 
clinical groups: Patients with different etiological factors (autoimmune, unknown) causing coma- 9 cases 
were included in the first group. We diagnosed non-convulsive status epilepticus (NCSE) in 4 cases from 
the first group. 13 patients with traumatic brain injury were included in the second group. In 3 cases of this 
group NCSE was found. The patients with oncological diseases and secondary brain damages was exclude. 
All patient underwent the following studies:   
1. Long-term EEG monitoring in dynamics 
2. Brain CT or MRT in dynamics 
3.  Objective neurological status (by GCS) 
4. Other basic clinical and Para clinical studies. 
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Results. In 3 cases of I group NCSE with refractory and super refractory developing was 
observed and in 2 cases of II group refractory SE was mentioned. 
Table 1 shows EEG patterns in all cases of NCSE from both groups.  
 
Table 1. Long-term EEG monitoring shows development NSCE in all cases in dynamic. 
Number of patient GCS EEG patterns 
2 4-6 Lateralized periodic discharges (LPDs) 
2 4-5 Bilateral periodic discharges (BPDs) 
3 3-4 Generalized periodic discharges (PDs) 
 
 
Fig. 1. Precious EEG data. Super-refractory SE. 
 
Fig. 2. MRI data of patients with autoimmune encephalitis. 
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Fig. 3. EEG data of super-refractory NCSE in patients with autoimmune encephalitis (In dynamics). 
 
Fig. 4. MRI data in dynamics. 
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Fig. 5. Patient with a refractory NCSE with Lateralized Periodic Discharges (LPDs). 
 
Fig. 6. MRI finding in this case. 
World Science 9(70), 2021 
 
RS Global 5 
 
 
Fig. 7. EEG changes in dynamics (without LPDs). 
 
Fig. 8. MRI changes in dynamics. 
For management of SE we have used treatment with Valproate Acid (VPA), Levetiracetam 
(LEV) and Carbamazepine (CBZ) in high doses. 
Fig. 1. shows super-refractory SE EEG monitoring findings- Bilateral periodic discharges 
(BPDs). 
Fig. 2. shows MRI finding in this case. 
Fig. 4. shows super-refractory SE. In this case, we used VPA, LEV and CBZ together with 
intravenous Propofol infusion (4 mg/kg/day), pulse corticosteroid therapy with Methylprednisolone, 
Thiopental and Ketamine infusion –dosage 2.75 mg/kg.  (3 days). Super refractory SE was continued. 
EEG monitoring shows generalized periodic discharges (PDs)-negative dynamics. 
In additional we used plasma exchange (PE), intravenous immunoglobulin (IVIG). Regardless 
of all these EEG dynamics was negative and MRI study revealed negative radiological changes. We 
have got depressing of brain activity while used Thiopental infusion. We have received maximal 
depression of brain activity and full control under convulsion. Of course, we have positive MRI 
dynamics in development of main disease (Fig. 4).  
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All cases of refractory and super-refractory SE were hard to be managed and prevented from 
developing severe brain damages. Figures 5, 6, 7, 8 show EEG and MRI data dynamics of refractory NCSE. 
Conclusions. Refractory and super refractory NCSE have severe clinical developments. It is 
difficult to manage each case and it needs treated individually. 
Outcome of these cases depends on what is the cause of initial disease and its severeness. 
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